NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as injectable and oral anti-influenza nanoviricide drug for H7N9, Bird Flu H5N1, other Highly Pathogenic Influenzas, Epidemic Influenzas, and Seasonal Influenzas; DengueCide, an anti-dengue nanoviricide which is in pre-clinical development; and HIVCide, an anti-human immunodeficiency virus drug candidate. It is also developing HerpeCide, a skin cream for the treatment of cold sores and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Phone+1-203-9376137
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees7
Next Earnings Date11/25/2019 (Estimated)
OptionableOptionable
NanoViricides (NYSEAMERICAN:NNVC) Frequently Asked Questions
What is NanoViricides' stock symbol?
NanoViricides trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NNVC."
When did NanoViricides' stock split? How did NanoViricides' stock split work?
Shares of NanoViricides reverse split on Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of NanoViricides stock prior to the reverse split would have 5 shares after the split.
How were NanoViricides' earnings last quarter?
NanoViricides Inc (NYSEAMERICAN:NNVC) announced its quarterly earnings results on Tuesday, February, 19th. The company reported ($0.68) EPS for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.08. View NanoViricides' Earnings History.
When is NanoViricides' next earnings date?
Has NanoViricides been receiving favorable news coverage?
Media coverage about NNVC stock has been trending somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NanoViricides earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for NanoViricides.
Are investors shorting NanoViricides?
NanoViricides saw a decline in short interest in the month of October. As of October 31st, there was short interest totalling 137,100 shares, a decline of 6.5% from the September 30th total of 146,600 shares. Based on an average daily volume of 42,700 shares, the days-to-cover ratio is currently 3.2 days. Approximately 5.0% of the shares of the stock are short sold. View NanoViricides' Current Options Chain.
Who are some of NanoViricides' key competitors?
Some companies that are related to NanoViricides include Patrys (PAB), Antisense Therapeutics (ANP), Avivagen (VIV), China Pharma (CPHI), Sareum (SAR), Cathay International (CTI), N4 Pharma (N4P), Bayer (BAYN), HedgePath Pharmaceuticals (MAYNF), OTSUKA HOLDINGS/ADR (OTSKY), Roche (SNYNF), Roche (RHHVF), Sanofi (SAN) and SINR PHAR/PAR VTG FPD 0.01 (SPH).
What other stocks do shareholders of NanoViricides own?
Who are NanoViricides' key executives?
NanoViricides' management team includes the folowing people:
- Dr. Anil R. Diwan, Chairman, Pres & Sec. (Age 60)
- Ms. Meeta R. Vyas SB, MBA, Chief Financial Officer (Age 60)
- Dr. Eugene Seymour, Chief Exec. Officer Emeritus (Age 78)
- Dr. Randall W. Barton Ph.D., Chief Scientific Officer & Chief Regulatory Officer (Age 72)
- Dr. Irach B. Taraporewala, Consultant & Director (Age 63)
Who are NanoViricides' major shareholders?
Which institutional investors are selling NanoViricides stock?
How do I buy shares of NanoViricides?
Shares of NNVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is NanoViricides' stock price today?
One share of NNVC stock can currently be purchased for approximately $2.10.
How big of a company is NanoViricides?
What is NanoViricides' official website?
How can I contact NanoViricides?
NanoViricides' mailing address is 1 Controls Dr, SHELTON, CT 06484-6153, United States. The company can be reached via phone at +1-203-9376137.
MarketBeat Community Rating for NanoViricides (NYSEAMERICAN NNVC)
MarketBeat's community ratings are surveys of what our community members think about NanoViricides and other stocks. Vote "Outperform" if you believe NNVC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NNVC will underperform the S&P 500 over the long term. You may vote once every thirty days.
